Conbercept in Choroidal Neovascularization Secondary to Uveitis
Status:
Unknown status
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that it is safe and effective to treat patients with choroidal
neovascularisation (abnormal blood vessels growing under the retina) secondary to uveitis
with Conbercept.
This will be a randomized, placebo-controlled trial. 20 patients will receive three
injections of Conbercept into the affected eye (and repeated injections if required), and 20
patients will receive three sham injections requiring no needle stick, but making the patient
unaware of whether or not he received active treatment.
Outcome of the two treatment groups will be compared after one year.